These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30833304)

  • 1. ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
    Saad MI; Alhayyani S; McLeod L; Yu L; Alanazi M; Deswaerte V; Tang K; Jarde T; Smith JA; Prodanovic Z; Tate MD; Balic JJ; Watkins DN; Cain JE; Bozinovski S; Algar E; Kohmoto T; Ebi H; Ferlin W; Garbers C; Ruwanpura S; Sagi I; Rose-John S; Jenkins BJ
    EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30833304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis.
    Saad MI; McLeod L; Yu L; Ebi H; Ruwanpura S; Sagi I; Rose-John S; Jenkins BJ
    Carcinogenesis; 2020 Jun; 41(4):527-538. PubMed ID: 31257400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.
    Hoang VT; Nyswaner K; Torres-Ayuso P; Brognard J
    J Biol Chem; 2020 Jun; 295(25):8470-8479. PubMed ID: 32358059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytosolic DNA sensor AIM2 promotes KRAS-driven lung cancer independent of inflammasomes.
    Alanazi M; Weng T; McLeod L; Gearing LJ; Smith JA; Kumar B; Saad MI; Jenkins BJ
    Cancer Sci; 2024 Jun; 115(6):1834-1850. PubMed ID: 38594840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1.
    Shin DH; Kim SH; Choi M; Bae YK; Han C; Choi BK; Kim SS; Han JY
    Oncogene; 2022 Jan; 41(2):280-292. PubMed ID: 34743207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic dependency on STAT3 serine phosphorylation in KRAS mutant lung cancer.
    Alhayyani S; McLeod L; West AC; Balic JJ; Hodges C; Yu L; Smith JA; Prodanovic Z; Bozinovski S; Kumar B; Ruwanpura SM; Saad MI; Jenkins BJ
    Oncogene; 2022 Feb; 41(6):809-823. PubMed ID: 34857889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.
    Hill KS; Erdogan E; Khoor A; Walsh MP; Leitges M; Murray NR; Fields AP
    Oncogene; 2014 Apr; 33(16):2134-44. PubMed ID: 23604119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. iRhom2 regulates ERBB signalling to promote KRAS-driven tumour growth of lung cancer cells.
    Sieber B; Lu F; Stribbling SM; Grieve AG; Ryan AJ; Freeman M
    J Cell Sci; 2022 Sep; 135(17):. PubMed ID: 35971826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.
    Van Schaeybroeck S; Kyula JN; Fenton A; Fenning CS; Sasazuki T; Shirasawa S; Longley DB; Johnston PG
    Cancer Res; 2011 Feb; 71(3):1071-80. PubMed ID: 21148749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Soluble IL-6R but Not ADAM17 Activation Drives Mononuclear Cell Migration in Tissue Inflammation.
    Schumacher N; Schmidt S; Schwarz J; Dohr D; Lokau J; Scheller J; Garbers C; Chalaris A; Rose-John S; Rabe B
    J Immunol; 2016 Nov; 197(9):3705-3715. PubMed ID: 27698010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
    Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
    Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
    Kim JY; Welsh EA; Fang B; Bai Y; Kinose F; Eschrich SA; Koomen JM; Haura EB
    Mol Cancer Res; 2016 Oct; 14(10):1019-1029. PubMed ID: 27422710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
    Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
    Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
    Green S; Trejo CL; McMahon M
    Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression.
    Kim DI; Lee SJ; Lee SB; Park K; Kim WJ; Moon SK
    Carcinogenesis; 2008 Sep; 29(9):1701-9. PubMed ID: 18296682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
    Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
    Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-6 production induced by leptin treatment promotes cell proliferation in an Apc (Min/+) colon epithelial cell line.
    Fenton JI; Hursting SD; Perkins SN; Hord NG
    Carcinogenesis; 2006 Jul; 27(7):1507-15. PubMed ID: 16597643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of interleukin-8 secretion and activation of ERK1/2, p38 MAPK signaling pathways by thrombin in dermal fibroblasts.
    Wang L; Luo J; Fu Y; He S
    Int J Biochem Cell Biol; 2006; 38(9):1571-83. PubMed ID: 16697690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance.
    Gao X; Chen G; Gao C; Zhang DH; Kuan SF; Stabile LP; Liu G; Hu J
    Mol Oncol; 2017 Jun; 11(6):628-639. PubMed ID: 28306189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.